Hormonal
In obese patients with type 2 diabetes, untreated obstructive sleep apnea (OSA) progresses rapidly, with AHI increasing by approximately 4 events per hour over one year even without weight gain.
If you have type 2 diabetes and sleep apnea, do not assume that staying at your current weight means your sleep apnea will stay stable. Without treatment or weight loss, your sleep apnea severity tends to worsen by about 4 events per hour each year. Early intervention is crucial to prevent this progression.
The DSE group, which was weight stable (−0.6 kg) over 1 year, had a mean increase in AHI of 4 events per hour, a statistically significant difference... This finding suggests that untreated OSA in this age group has a relatively rapid natural progression, increasing 4 events per hour in just 1 year.
Why this rating
Derived from the control group of a high-quality RCT.
Source
A Randomized Study on the Effect of Weight Loss on Obstructive Sleep Apnea Among Obese Patients With Type 2 Diabetes<subtitle>The Sleep AHEAD Study</subtitle><alt-title>Effect of Weight Loss on Obstructive Sleep Apnea</alt-title>
Gary D. Foster · Archives of Internal Medicine · 2009
DOI 10.1001/archinternmed.2009.266
More from this paper
- Weight loss achieved through an intensive lifestyle intervention significantly reduces the severity of obstructive sleep apnea (OSA) in obese patients with type 2 diabetes, with greater weight loss correlating to greater AHI reduction.Strong
- Men and patients with higher baseline OSA severity experience greater reductions in Apnea-Hypopnea Index (AHI) from weight loss interventions.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →